Early test of Next-Gen RSV vaccine begins
NCT ID NCT07071558
Summary
This early-stage study is testing different versions of a new RSV vaccine made with mRNA technology. It will involve 240 healthy adults aged 18-49 to check if the vaccines are safe and if they trigger a good immune response against the virus. Participants will receive one shot and be followed for about six months to monitor for any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS IMMUNIZATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site # 0361001
Camberwell, Victoria, 3124, Australia
-
Site # 0361002
Bayswater, Victoria, 3153, Australia
-
Site # 0361003
Wollongong, New South Wales, 2500, Australia
-
Site # 0361004
Southport, Queensland, 4215, Australia
-
Site # 0361005
Morayfield, Queensland, 4506, Australia
-
Site # 0361006
Brisbane, Queensland, 4006, Australia
Conditions
Explore the condition pages connected to this study.